Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 4/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255702 | 0.88 | ALDH1A1 (0.47) | PDCD1CD274LTA4HALDH1A1NPC1 | |
| SCHEMBL20255353 | 0.88 | ALDH1A1 (0.47) | PDCD1CD274LTA4HALDH1A1NPC1 | |
| SCHEMBL18291479 | 0.85 | ALDH1A1 (0.58) | LTA4HALDH1A1MCHR1 | |
| SCHEMBL20037672 | 0.85 | ALDH1A1 (0.58) | LTA4HALDH1A1MCHR1 | |
| SCHEMBL20037663 | 0.85 | ALDH1A1 (0.58) | LTA4HALDH1A1MCHR1 | |
| SCHEMBL18291538 | 0.84 | RAB9A (0.52) | PDCD1CD274LTA4HALDH1A1NPC1 | |
| SCHEMBL20037938 | 0.81 | PDE1B (0.36) | MEN1KMT2AATM | |
| SCHEMBL18291572 | 0.80 | BRD4 (0.45) | PDCD1CD274LTA4HBRD4MEN1 | |
| SCHEMBL18587341 | 0.77 | FUCA1 (0.47) | FUCA1ALDH1A1BRD4 | |
| SCHEMBL20249107 | 0.76 | CCR9 (0.41) | PDCD1CD274LTA4HBRD4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PDCD1 344/4885CD274 1164/4885LTA4H 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.